David P Southwell Ptc Therapeutics, Inc. (PTCT) insider trading activity

David P Southwell is of PTC THERAPEUTICS, INC.. Currently has a direct ownership of 20,850 shares of PTCT, which is worth approximately $1.57 Million. The most recent transaction as insider was on Jan 02, 2026, when has been sold 4,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 20.9K

23.74% 3M change

23.74% 12M change

Total Value Held $1.57 Million

DAVID P SOUTHWELL Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 02 2026	BUY Grant, award, or other acquisition	-	4,000 Added 16.1%	20,850 Common Stock
Sep 09 2025	SELL Open market or private sale	$700,080 $58.34 p/Share	12,000 Reduced 41.59%	16,850 Common Stock
Sep 09 2025	BUY Exercise of conversion of derivative security	$370,320 $30.86 p/Share	12,000 Added 29.38%	28,850 Common Stock
Jan 03 2025	BUY Grant, award, or other acquisition	-	4,000 Added 19.18%	16,850 Common Stock
May 08 2024	SELL Bona fide gift	-	1,650 Reduced 11.38%	12,850 Common Stock
Feb 15 2024	BUY Grant, award, or other acquisition	-	4,000 Added 21.62%	14,500 Common Stock
Apr 17 2023	SELL Open market or private sale	$583,564 $51.06 p/Share	11,429 Reduced 52.12%	10,500 Common Stock

Apr 17 2023	BUY Exercise of conversion of derivative security	$205,836 $18.01 p/Share	11,429 Added 34.26%	21,929 Common Stock
Mar 31 2023	SELL Open market or private sale	$128,678 $50.05 p/Share	2,571 Reduced 19.67%	10,500 Common Stock
Mar 31 2023	BUY Exercise of conversion of derivative security	$46,303 $18.01 p/Share	2,571 Added 16.44%	13,071 Common Stock
Mar 27 2023	SELL Open market or private sale	$453,800 $45.38 p/Share	10,000 Reduced 48.78%	10,500 Common Stock
Mar 27 2023	BUY Exercise of conversion of derivative security	$270,500 $27.05 p/Share	10,000 Added 32.79%	20,500 Common Stock
Jan 05 2023	BUY Grant, award, or other acquisition	-	4,000 Added 27.59%	10,500 Common Stock
Jan 07 2022	BUY Grant, award, or other acquisition	-	3,200 Added 32.99%	6,500 Common Stock
Jan 06 2021	BUY Grant, award, or other acquisition	-	1,650 Added 33.33%	3,300 Common Stock
Oct 16 2020	SELL Open market or private sale	$1,399,950 $51.85 p/Share	27,000 Reduced 94.24%	1,650 Common Stock
Oct 16 2020	BUY Exercise of conversion of derivative security	$298,080 $11.04 p/Share	27,000 Added 66.42%	13,650 Common Stock

Also insider at

RCKT

ROCKET PHARMACEUTICALS, INC. Healthcare

TCRX

TScan Therapeutics, Inc. Healthcare

Chief Executive Officer

DPS